Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 1/20 | 0.42 |
| ▸ | MAP4K4 | O95819 | 5/20 | 0.41 |
| ▸ | TSHR | P16473 | 4/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.41 |
| ▸ | AURKA | O14965 | 2/20 | 0.40 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 2/20 | 0.39 |
| ▸ | JAK3 | P52333 | 2/20 | 0.39 |
| ▸ | CLK4 | Q9HAZ1 | 4/20 | 0.38 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.38 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.38 |
| ▸ | PAK4 | O96013 | 1/20 | 0.38 |
| ▸ | ABL1 | P00519 | 1/20 | 0.38 |
| ▸ | LCK | P06239 | 1/20 | 0.38 |
| ▸ | CSF1R | P07333 | 1/20 | 0.38 |
| ▸ | RET | P07949 | 1/20 | 0.38 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12015610 | 0.86 | MAP4K4 (0.41) | MAP4K4PIK3CDAURKARPS6KB1JAK2 | |
| SCHEMBL1598841 | 0.86 | MAP4K4 (0.41) | MAP4K4PIK3CDAURKAJAK2JAK3 | |
| SCHEMBL4167501 | 0.86 | MAP4K4 (0.41) | MAP4K4PIK3CDAURKARPS6KB1JAK2 | |
| SCHEMBL4183370 | 0.86 | MAP4K4 (0.41) | MAP4K4PIK3CDAURKARPS6KB1JAK2 | |
| SCHEMBL4184872 | 0.85 | MAP4K4 (0.41) | NTRK1MAP4K4PIK3CDAURKARPS6KB1 | |
| SCHEMBL4189208 | 0.84 | MAP4K4 (0.41) | MAP4K4PIK3CDAURKARPS6KB1JAK2 | |
| SCHEMBL27781324 | 0.84 | PIK3CD (0.39) | MAP4K4PIK3CDAURKARPS6KB1JAK2 | |
| SCHEMBL12020057 | 0.83 | PIK3CD (0.49) | TSHRTP53SMN1; SMN2HSD17B10PIK3CD | |
| SCHEMBL27781222 | 0.83 | PIK3CD (0.40) | TSHRTP53SMN1; SMN2HSD17B10PIK3CD | |
| SCHEMBL4182182 | 0.83 | PIK3CD (0.46) | TSHRTP53SMN1; SMN2HSD17B10PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200048265-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2020-02-13 | — | — | US | disclosed |
| US-20200048265-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2020-02-13 | — | — | US | disclosed |
| US-20180105532-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2018-04-19 | — | — | US | disclosed |
| US-20180105532-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2018-04-19 | — | — | US | disclosed |
| US-20180105532-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2018-04-19 | — | — | US | disclosed |
| US-9873701-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2018-01-23 | — | — | US | disclosed |
| US-9873701-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2018-01-23 | — | — | US | disclosed |
| US-9873701-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2018-01-23 | — | — | US | disclosed |
| EP-3045458-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | Amgen, Inc (US) | 2016-07-20 | — | — | EP | disclosed |
| EP-3045458-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | Amgen, Inc (US) | 2016-07-20 | — | — | EP | disclosed |
| US-8193199-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2012-06-05 | — | — | US | disclosed |
| US-8193199-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2012-06-05 | — | — | US | disclosed |
| US-8193199-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2012-06-05 | — | — | US | disclosed |
| CN-101715453-A | Heterogeneous ring compound and application thereof | AMGEN INC | 2010-05-26 | — | — | CN | disclosed |
| EP-2137186-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | Amgen Inc. (US) | 2009-12-30 | — | — | EP | disclosed |
| US-20090137581-A1 | Heterocyclic compounds and their uses | AMGEN INC. | 2009-05-28 | — | — | US | disclosed |
| US-20090137581-A1 | Heterocyclic compounds and their uses | AMGEN INC. | 2009-05-28 | — | — | US | disclosed |
| US-20090137581-A1 | Heterocyclic compounds and their uses | AMGEN INC. | 2009-05-28 | — | — | US | disclosed |
| WO-2008118468-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2008-10-02 | — | — | WO | disclosed |
| WO-2008118468-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2008-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200048265-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, BCL9, MALT1 | NTRK1 2199/4885MAP4K4 1200/4885TSHR 1588/4885 |
| US-20090137581-A1 | Heterocyclic compounds and their uses | MCL1, BCL9, MALT1 | NTRK1 2199/4885MAP4K4 1200/4885TSHR 1588/4885 |
| US-20180105532-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, BCL9, MALT1 | NTRK1 2199/4885MAP4K4 1200/4885TSHR 1588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.